Down the Road: New Drugs, New Treatment Strategies and Other Changes Coming Your Way
May 5, 2017
raltegravir QD A once-daily dose of Isentress. Approval expected in May.
ibalizumab A monoclonal antibody entry inhibitor given by infusion; an injectible may become available. Approval expected in June.
sofosbuvir/valpatasvir/voxilaprevir (GS-9857) A single-tablet regimen (STR) made up of direct-acting antivirals, two of them pangenotypic.
glecaprevir/pibrentasvir A pangenotypic regimen with two direct-acting antivirals.
bictegravir/emtricitabine/tenofovir alafenamide (GS-9883) An STR containing an integrase inhibitor (INSTI) that does not require boosting.
darunavir/cobicistat/tenofovir alafenamide/emtricitabineThe first single-tablet regimen containing a protease inhibitor.
fostemsavirAn HIV entry inhibitor that targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs.
doravirine/tenofovir disoproxil fumarate/lamivudine A single-tablet regimen containing a non-nuke that may work in those who have developed resistance to other non-nukes, with no food restrictions.
dolutegravir/rilpivirine New co-formulation of already approved INSTI and non-nuke; first STR using only two drugs.
Sustiva (efavirenz) expected to go generic first quarter.
efavirenz/tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; STR similar to Atripla.
Tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; fixed-dose combination similar to Truvada. Not studied or recommended for use as PrEP.
cabotegravir/rilpivirine LA A long-acting injectable containing an INSTI and an NNRTI.
Prezista (darunavir)goes generic.
Emtriva (emtricitabine) goes generic.
Truvada (tenofovir disoproxil fumarate/emtricitabine) goes generic.
Atripla (efavirenz/tenofovir disoproxil fumarate/ emtricitabine) goes generic.
Information courtesy of the Fair Pricing Coalition. For more, go to fairpricingcoalition.org.
This article was provided by Test Positive Aware Network. It is a part of the publication Positively Aware. Visit TPAN's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)